Transvenous low energy internal cardioversion for atrial fibrillation: A review of clinical applications and future developments

PACE - Pacing and Clinical Electrophysiology

Volumn 24, Issue 1, 2001, Pages 99-107

  Boriani, Giuseppe ^a,b,c   Biffi, Mauro ^a,b   Camanini, Claudia ^a,b   Luceri, Richard M ^a,b   Branzi, Angelo ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Florida Arrhythmia Consultants   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atrial fibrillation; Cardioversion; Defibrillation; Defibrillation threshold; Electrophysiological study

Indexed keywords

CARDIOVERSION; COST BENEFIT ANALYSIS; DEFIBRILLATION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; QRS COMPLEX; REVIEW; RISK FACTOR; SHOCK; SINUS RHYTHM; TREATMENT INDICATION;

EID: 0035113287     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2001.00099.x     Document Type: Review

References (104)

1. Epidemiologic features of chronic atrial fibrillation: The Framingham Study
2. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study
3. Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation
4. Impact of atrial fibrillation on mortality, stroke, and medical costs
5. Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm
6. Rhythm management in atrial fibrillation with a primary emphasis on pharmacological therapy: Part 2
7. Acute treatment of atrial fibrillation
8. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease
9. Conversion of recent-onset atrial fibrillation to sinus rhythm: Effects of different drug protocols
10. Management of atrial fibrillation
11. Pharmacological treatment of atrial fibrillation: A review on prevention of recurrences and control of ventricular response
12. Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm
13. Rhythm management in atrial fibrillation with a primary emphasis on pharmacological therapy: Part 3
14. Treatment strategies for atrial fibrillation
15. New method for terminating cardiac arrhythmias
16. Optimal technique for electrical cardioversion of atrial fibrillation
17. Transthoracic cardioversion of atrial fibrillation: Standard techniques and new advances
18. Electrical conversion of atrial fibrillation: Immediate and long term results and selection of patients
19. Factors determining success and energy requirements for cardioversion of atrial fibrillation
20. A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion
21. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
22. Relation between transcardiac and transthoracic current during defibrillation in humans
23. Internal low energy cardioversion for the treatment of cardiac arrhythmias
24. High energy transcatheter cardioversion of chronic atrial fibrillation
25. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation
26. Internal cardioversion of atrial fibrillation in sheep
27. Catheter-based atrial defibrillation
28. Lead systems for atrial defibrillation
29. Ventricular proarrhythmic effects of vantricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation
30. Low energy catheter cardioversion of atrial tachyarrhythmias
31. Atrial defibrillation: Can modifications in current implantable cardioverter-defibrillators achieve this?
32. The atrial defibrillator: A stand alone device or part of a combined dual-chamber system?
33. Efficacy and tolerability of transvenous low-energy cardioversion of paroxysmal atrial fibrillation in humans
34. Atrial defibrillation using a unipolar, single lead right ventricular to pectoral can system
35. Feasibility of atrial fibrillation detection and fuse of a preceding synchronization interval as a criterion for shock delivery in humans with atrial fibrillation
36. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation
37. Testing different biphasic wayeforms and capacitances: Effect on atrial defibrillation threshold and pain perception
38. Pain threshold for low-energy intracardiac cardioversion of atrial fibrillation with low or no sedation
39. Low-energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system
40. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold
41. Low-energy cardioversion of spontaneous atrial fibrillation. Immediate and long-term results
42. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation
43. Changes in intracardiac atrial cardioversion threshold at rest and during exercise
44. Transvenous ICD leads for single and dual chamber ICDs: Actual and future developments
45. The effect of biphasic waveform tilt in transvenous atrial defibrillation
46. Efficacy and tolerability in fully conscious patients of transvenous low-energy internal atrial cardioversion for atrial fibrillation
47. Influence of active pectoral can on transvenous atrial cardioversion threshold in patients with implantable cardioverter-defibrillator
48. Insights into lead configurations and initial atrial defibrillation thresholds in a dual-chambar active can defibrillator
49. Effect of electrode length on atrial defibrillation thresholds
50. Atrial defibrillation with a transvenous lead
51. Internal low energy cardioversion: A therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion
52. Internal cardioversion in two patients with atrial fibrillation refractory to external cardioversion
53. Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks
54. Leads technology
55. Temporary transvenous cardioversion and defibrillation: A new method for practical tachyarrhythmia management
56. Importance of electrode design, lead configuration and impedance for successful low energy transcatheter atrial defibrillation in dogs
57. Transvenous atrial cardioversion: A randomized comparison between catheters with different coil length
58. Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation
59. Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low energy human transvenous atrial defibrillation using an implantable lead system
60. Optimization of shocking lead configuration for transvenous atrial defibrillation
61. Internal atrial defibrillation in humans. Improved efficacy of biphasic waveforms and the importance of phase duration
62. Transvenous internal cardioversion for atrial fibrillation: A randomized study on defibrillation threshold and tolerability of asymmetrical compared with symmetrical shocks
63. Marked reduction in internal atrial defibrillation thresholds with dual-current pathways and sequential shocks in humans
64. Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations
65. Tolerability of internal low-energy shock strengths currently needed for endocardial atrial cardioversion
66. Intra-atrial defibrillation of human atrial fibrillation
67. Clinical transvenous cardioversion of recurrent life-threatening ventricular tachyarrhythmias: Low energy synchronized cardioversion of ventricular tachycardia and termination of ventricular fibrillation in patients using a catheter electrode
68. Rounded biphasic waveform reduces energy requirements for transvenous catheter cardioversion of atrial fibrillation and flutter
69. Patient discomfort after transvenous catheter cardioversion of atrial fibrillation with rounded waveforms. Initial results
70. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation
71. Single shock endocavitary low energy intracardiac atrial cardioversion of chronic atrial fibrillation
72. Ventricular fibrillation resulting from synchronized internal atrial defibrillation in a patient with ventricular preexcitation
73. Management of patients with atrial fibrillation
74. Management of cardiac arrhythmias: Pharmacological, electrical and surgical techniques
75. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for antiacoagulant therapy
76. Atrial fibrillation: Current knowledge and recommendations for management
77. Low energy internal atrial cardioversion in atrial fibrillation lasting more than one year
78. Efficacy of a new balloon catheter for internal cardioversion of chronic atrial fibrillation without anaesthesia
79. Anti-thrombotic therapy in atrial fibrillation
80. Antithrombotic therapy in atrial fibrillation
81. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation
82. Anticoagulation for cardioversion of atrial arrhythmia
83. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation induced electrical remodeling of the atria?
84. Long term outcome in patients with chronic atrial fibrillation after successful internal cardioversion
85. Evaluation of atrial refractoriness and atrial fibrillation inducibility immediately after internal atrial cardioversion in patients with chronic persistent atrial fibrillation
86. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats
87. Electrical remodeling in atrial fibrillation. Time course and mechanisms
88. Effect of atrial fibrillation on atrial refractoriness in humans
89. Electrophysiological characteristics of the human atria after cardioversion of persistent atrial fibrillation
90. Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man
91. Hemodynamic effects and clinical determinants of defibrillation threshold for transvenous atrial defibrillation using biatrial biphasic shocks in patients with chronic atrial fibrillation
92. Immediate reinitiation of atrial fibrillation following internal atrial defibrillation
93. Spontaneous reinitiation of atrial fibrillation following transvenous atrial defibrillation
94. Incidence and mode of onset of early reinitiation of atrial fibrillation after successful internal cardioversion and its prevention by intravenous sotalol
95. Atrioverter: An implantable device for the treatment of atrial fibrillation
96. Verapamil reduces tachycardia-induced electrical remodeling of the atrial
97. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans
98. Tachycardia-induced change of atrial refractory period in humans. Rate dependency and effects of antiarrhythmic drugs
99. Nonpharmacologic therapies for atrial fibrillation
100. Atrial fibrillation follow up investigation of rhythm management. The AFFIRM study design
101. Implantable atrial and dual chamber defibrillators
102. Clinical experience with a dual chamber implantable cardioverter defibrillator in patients with atrial fibrillation and flutter
103. Elective countershock in unanesthetized patients with use of a transesophageal electrode
104. Transesophageal cardioversion